



TM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Craig A. Coburn et al.	
Serial No.:	10/563,538	Case No.: 21455YP
Filing Date:	December 19, 2005	
For:	N-ALKYL PHENYLCARBOXAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE	

Commissioner for Patents  
P.O. BOX 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Services as first class mail in an envelope addressed to:

Commissioner for Patents, P. O. Box 1450,  
Alexandria, VA 22313-1450, on the date appearing  
Below.

MERCK & CO., INC.

By [Signature] Date 11-15-2004


This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

References A-C on the accompanying PTO 1440 form were cited in the European Search Report for this application. A copy of the European Search Report is enclosed with this Information Disclosure Statement.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application. Accordingly, it is believed that no fee is due. Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By   
John C. Todaro, Reg. No. 36,036  
Attorney for Applicant

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-0125

Date: November 15, 2006

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE**  
**STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**COMPLETE IF KNOWN**

<b>Application Number</b>	10/563,538
<b>Filing Date</b>	May 24, 2006
<b>First Named Inventor</b>	Craig A. Coburn
Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	21455YP

Sheet	1	of	1
-------	---	----	---

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	A		WO 2004/043916		Merck & Co., Inc.	05/27/2004
	B		WO 03/043975		Elan Pharmaceuticals, Inc. and	
					Pharmacia & Upjohn Company	05/30/2003
	C		WO 02/02506		Elan Pharmaceuticals, Inc.	01/10/2002

Examiner  
Signature

Date  
Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006